Loading
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Latest filing published 05 Oct 2026 for Arbutus Biopharma Corp, €39.6M. Read the official filing
Filing timeline
BuySaleRoivant Sciences Ltd.
Insider track record
Disclosed buys
3
Disclosed sells
0
Signal history
Closed purchases
Market purchases
3
Positive at T+90
33%
Median T+90
-6.1%
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +28.7%Entry US$26.00 · Close 05 Oct 2026 US$33.47
- +9.0%Entry US$23.86 · Close at T+365 US$26.01
- +307.1%Entry US$9.19 · Close at T+365 US$37.41
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Roivant Sciences Ltd.: trading record in brief
This profile gathers the share dealings of Roivant Sciences Ltd. across 2 companies, led by Immunovant, Inc. and Arbutus Biopharma Corp. Between 2 August 2021 and 1 October 2026, the trades on record add up to 7 filings.
No open-market sale appears; the market trades are 3 purchases worth €629.6M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 1 share grant.
The median purchase comes to €298.1M. On 1 out of 3 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. For 3 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 33% of cases, with a median move of -6.1%. These figures describe past trades and do not predict future prices.
On 5 October 2026 came the latest disclosure, a transaction for €39.6M in Arbutus Biopharma Corp. The last purchase on record was published on 12 December 2025, which is 310 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Roivant Sciences Ltd.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations7 total
8,967,383 shares@ US$5.00Common SharesSEC:0001140361-26-038692:0
16,666,666 shares@ US$21.0037.7% of flowCommon Stock, $0.0001 par value per shareSEC:0001140361-25-045409:0
Canonical exit: 12 Mar 2026 (T+90)
16,845,010 shares@ US$20.0041.5% of flowCommon Stock, $0.0001 par value per shareSEC:0001140361-25-001188:0
Canonical exit: 13 Apr 2025 (T+90)
4,473,684 shares@ US$38.0020.5% of flowCommon Stock, $0.0001 par value per shareSEC:0001140361-23-046976:0
416,667 shares@ US$6.000.3% of flowCommon Stock, $0.0001 par value per shareSEC:0001140361-22-036652:0
Canonical exit: 4 Jan 2023 (T+90)
22,833,922 sharesCommon shares, without par valueSEC:0000950103-21-016172:0
17,021,276 sharesCommon Stock, $0.0001 par value per shareSEC:0001104659-21-099083:0
7 of 7 declarations
